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ABSTRACT
Breast cancer is already the most common malignancy affecting women 
worldwide, and evidence is mounting that breast cancer induced by circadian 
disruption (CD) is a warranted concern. Numerous studies have investigated various 
aspects of the circadian clock in relation to breast cancer, and evidence from these 
studies indicates that melatonin and the core clock genes can play a crucial role in 
breast cancer development. Even though epigenetics has been increasingly recognized 
as a key player in the etiology of breast cancer and linked to circadian rhythms, 
and there is evidence of overlap between epigenetic deregulation and breast cancer 
induced by circadian disruption, only a handful of studies have directly investigated 
the role of epigenetics in CD-induced breast cancer. This review explores the circadian 
clock and breast cancer, and the growing role of epigenetics in breast cancer 
development and circadian rhythms. We also summarize the current knowledge and 
next steps for the investigation of the epigenetic link in CD-induced breast cancer.
INTRODUCTION
Breast cancer is currently the most common 
malignancy affecting women worldwide. It accounts for 
25% of all cancers in women and caused 522,000 deaths 
worldwide in 2012 [1]. Breast cancer is also present in 
human males, with males having poorer outcomes due 
to delays in diagnosis and estimates by the American 
Cancer Society indicating that there will be around 2350 
new cases of male invasive breast cancer in the United 
States in 2015 [2, 3]. The development of breast cancer 
emerges through a multi-step process, encompassing 
progressive changes from a normal cell to hyperplasia, 
carcinoma in situ, invasive carcinoma, and metastasis, 
with the cancer either originating in the milk ducts, 
milk-producing lobules, or connective tissues [4–6]. 
Breast cancer tumours also vary in gene expression 
patterns and other characteristics, resulting in different 
classifications and treatment options.
Currently, breast cancers are separated into two main 
classes and four groups based on specific phenotypes. 
The two main classes are dependent on the hormone 
status of the cancer, with estrogen receptor (ER) and 
progesterone receptor (PR) positive cancers being part of 
the luminal class, and the ER and PR negative cancers 
being distinguished as non-luminal [7]. The luminal status 
of the breast cancer is then combined with the expression 
status of the erb-b2 receptor tyrosine kinase (ERBB2) 
gene, a proto-oncogene which encodes for the human 
epidermal growth factor receptor 2 (HER2) protein, in 
order to determine if an overabundance of HER2 plays 
a role in tumour progression and to classify the cancer 
into one of four specific groups: luminal A (group 1), 
luminal B (group 2), HER-2 positive (group 3), and triple 
negative (group 4) [7]. Groups 1 and 2 are the hormone 
positive breast cancers, with luminal A being HER2 
negative and luminal B being HER2 positive. Groups 3 
and 4 are the non-luminal cancers, and as the group names 
suggest, the HER2-positive group only expresses HER2 
and the triple negative group is negative for all three of 
the phenotypes tested.
Based on the four-group classification system 
discussed, breast cancer patient treatment options have 
become more specific and efficient, and the prognosis of 
patients has become better and more accurate. In terms 
of the luminal breast cancers, these tumours are less 
aggressive, lead to a better prognosis, and respond to 
more treatment options. For example, Tamoxifen (TAM), 
an ER antagonist drug, is the current treatment choice for 
groups 1 and 2 at any stage in pre- and post-menopausal 
women [8, 9]. However, not only is TAM treatment not 
a valid option for groups 3 and 4 because there is no 
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ER expression in these tumours, but non-luminal breast 
cancers are more aggressive, offer a poorer prognosis, 
and respond to fewer treatment options [8, 10]. As a 
result, a potential approach to treating non-luminal 
breast cancers is to reactivate ER activity through drugs 
such as 5-aza-2`deoxycytidine (5-aza) or Trichostatin A 
(TSA), and then apply TAM treatment or chemotherapy 
[8, 11, 12]. Although this approach may not be as efficient 
and proven as regular hormonal treatment, it represents 
a step in the right direction that was made possible by 
investigating the characteristics of different breast cancers.
In 2007, the International Agency for Research 
on Cancer (IARC) concluded “shift work that involves 
circadian disruption is probably carcinogenic to 
humans” [13]. Although this statement refers to shift 
work as a potential carcinogen, shift work is not the only 
potential cause of circadian disruption (CD). Time zone 
changes, jet lag, space travel, psychiatric disorders, and 
even light exposure from lamps and electronics during 
the evening hours can cause circadian disruption [14–18]. 
Furthermore, studies have shown that CD can promote 
the spontaneous development of a variety of tumours in 
a rodent model, and that CD may be linked to a higher 
risk of prostate cancer in men [19–21]. However, the 
most prominent link established thus far between CD 
and carcinogenesis has been in breast cancer, and recent 
case studies have supported the 2007 IARC claim by 
providing indirect evidence that shift workers are at a 
higher risk of developing breast cancer. Specifically, 
studies found that work after midnight significantly 
increased the risk of breast cancer in women when 
compared to day work, that the risk increased with the 
duration and accumulation of overnight shifts, and that 
rotating shifts between day and night is more disruptive 
than permanent night work [13, 22]. These case study 
findings, in combination with the fact that one third 
of the Canadian labour force is not working a regular 
daytime shift and that shift work may cause a higher 
prevalence of ER negative breast cancer, warrants further 
investigation into the mechanisms underlying breast 
carcinogenesis due to circadian disruption [23, 24]. 
By investigating the characteristics and mechanisms 
involved in CD-induced breast cancer, valuable insights 
and knowledge may materialize, thus potentially allowing 
for different treatment options to emerge and improving 
the prognosis of patients.
CIRCADIAN RHYTHMS
A circadian rhythm is any biological process 
that displays an endogenous, entrainable oscillation of 
approximately 24 hours, with these biological processes 
being controlled by a circadian system that is organized 
in a hierarchical manner. Acting as a link between the 
nervous and endocrine systems via the pituitary gland 
and containing a number of small nuclei, including the 
suprachiasmatic nucleus (SCN), the hypothalamus of the 
brain represents the top of a circadian hierarchy through 
the SCN [25, 26]. Guided by the activity of the SCN, 
numerous hormones and genes are entrained to 24-hour 
rhythms of expression and activity to ensure proper 
cellular function [26]. Amongst these circadian-regulated 
hormones is melatonin (MLT), a pineal hormone that has 
been shown to fluctuate based on environmental light and 
play a crucial role in breast cancer development [26, 27]. 
The core clock genes are among the circadian-regulated 
genes. Found in almost all nucleated cells of the human 
body, the core clock genes not only help maintain circadian 
rhythm activity in peripheral oscillators but may also play 
a significant role in breast cancer development [26, 27].
Suprachiasmatic nucleus
The paired suprachiasmatic nucleus of the anterior 
hypothalamus acts as a key oscillator of circadian 
rhythms by regulating downstream peripheral oscillators 
via endocrine and neural signals [28]. This “master” 
oscillator is composed of two distinct regions, a shell and 
a core [29]. The shell region exhibits uniform oscillations 
of activity, is not immediately responsive to photic 
stimulation, and can maintain an approximate 24 hour 
pattern of activity in the absence of environmental stimuli 
[30, 31]. Unlike the shell, the core does not display 
synchronized, rhythmic patterns of activity in the absence 
of an external input [32]. Instead, the core is externally 
synchronized by environmental light through non-visual, 
photic retinal ganglion cells [27, 30, 33]. Working 
together, the core interprets and analyzes information 
regarding the time of day and entrains the oscillator 
present within the shell [29]. The shell then regulates the 
output of the SCN, resulting in the organization of bodily 
processes on an environmentally synchronized schedule 
for optimal performance [29, 31].
In humans, many biochemical processes, such 
as hormone secretion, cell cycle, apoptosis, and gene 
expression, are entrained on a regular 24-hour rhythm 
by daily periods of light exposure. Repeated unnatural 
exposure to light during the dark phase of the circadian 
cycle, such as through shiftwork, disrupts the activity 
of the SCN and inhibits synchronizing of the circadian 
clock to the proper light-dark cycle [34]. Although the 
SCN has the capacity to adjust to new schedules, this 
adjustment does not occur instantly; instead, it occurs 
over a certain number of 24-hour cycles [27]. Evidence 
also shows that the majority of shift workers never 
actually entrain fully to the aberrant light-dark schedule, 
resulting in continuously desynchronized circadian 
rhythms [35, 36]. Furthermore, peripheral oscillators 
depend on the SCN for guidance. However, the SCN 
adapts faster than peripheral oscillators to environmental 
stimuli, and as a result, there is a lag that occurs which 
causes a desynchronizing between the SCN and the 
peripheral oscillators [26]. During this lag period, a 
multitude of rhythmic events can become disrupted, 
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resulting in circadian phase shifts that can lead to 
complications and disease [26].
Melatonin
Melatonin (MLT), a pineal hormone that plays a 
role in the control of sleep, is directly linked to circadian 
rhythm activity through the suprachiasmatic nucleus. As a 
result of this integration, not only does the concentration 
of MLT fluctuate during a circadian cycle, but the ability 
of melatonin to influence the SCN also changes [37]. 
Through a biological timing signal that is internally 
driven by the central pacemaker in the SCN, MLT is very 
abundant during the night and almost completely absent 
during the day, with sleep not being necessary to initiate 
the increase in melatonin levels but complete darkness 
being an absolute requirement [38, 39]. Therefore, 
aberrant exposure to light at nighttime can result in lower 
melatonin levels and potential complications.
As mentioned previously, TAM is the current 
treatment choice for ER-positive breast cancers [8, 9]. 
However, a recent study utilized a rodent model to provide 
evidence that dim light at night can induce resistance 
to TAM treatment in ER-positive tumours [40]. The 
resistance seems to be linked to lower nocturnal levels of 
melatonin because rats that did not have a disrupted MLT 
rhythm or rats that received nocturnal MLT replacement 
still responded to TAM treatment [40]. These results 
are striking because evidence has already emerged that 
shift work may result in a higher incident of ER negative 
breast cancer, thus indicating that CD-induced breast 
cancer may pose a very unique and serious problem in 
terms of treatment options [24]. Interestingly, the study 
also showed that endogenous circadian MLT increases 
tumour sensitivity to TAM, which is consistent with 
previous studies that illustrated the same findings 
[40–42]. These results add to the growing evidence 
for the potential of chronotherapy in cancer treatment. 
Human clinical trials utilizing a chronotherapy approach 
in the treatment of acute lymphoblastic leukemia and 
metastatic colorectal cancer have provided significant 
evidence of increased survival rates depending on the 
time of treatment within a 24-hour day [43]. In terms of 
breast cancer chronotherapy, a phase I human trial has 
provided preliminary evidence that chronomodulated 
infusion of a combination of chemotherapy drugs can 
result in acceptable toxicity, and a rodent model study has 
provided evidence for an optimal celecoxib dosing time 
based on based on the light-dark cycle [44, 45]. These 
findings, coupled with the fact that TAM activity is linked 
to circadian rhythms through MLT, provides a strong 
argument that chronotherapy is a logical and promising 
endeavour that needs to be explored in the treatment of 
breast cancer.
Evidence shows that melatonin appears to be involved 
in cancer development and growth. In experimental rat 
models of chemical carcinogenesis, the physiological 
melatonin signal suppresses the initiation phase of 
tumourigenesis by suppressing the damage and alterations 
caused by DNA adducts [39, 46]. This ability of melatonin 
to suppress DNA adduct damage is believed to be due to 
melatonin acting as a potent free-radical scavenger and/
or promoting repair of DNA once damage has occurred 
[39, 46]. Studies also show that at nocturnal concentrations, 
melatonin may exhibit biochemical and molecular oncostatic 
actions. In a rat MCF-7 breast cancer cell xenograft study, 
evidence showed that constant exposure to light resulted 
in deregulation of the circadian MLT rhythm, and that the 
tumour xenografts associated with constant light exposure 
showed significantly increased growth when compared 
to the light-dark groups [47]. Another study, utilizing 
DMBA induced mammary adenocarcinomas in female rats, 
illustrated that a constant dim light during the dark phase of 
the circadian cycle caused higher rates of tumour growth 
and lower levels of survival [48].
A possible explanation for the nocturnal, light-
induced tumour growth may be that lower levels of MLT 
cause increased metabolism of fatty acids and aberrations 
in cancer-dependent pathways. For example, melatonin 
can cause receptor-mediated inhibition of cyclic adenosine 
monophosphate (cAMP), resulting in downregulation of 
the transcriptional expression of ERα in human breast 
cancer cells and lower fatty acid metabolism by tumour 
cells through decreased fatty acid transport [39, 47, 49]. 
Calmodulin (CaM) activity, which plays a role in breast 
cancer tumour development by suppressing apoptosis 
and increasing survival through EGF-initiated activation 
of protein kinase B (Akt), is also lowered by melatonin 
activity through binding of the pineal hormone to CaM and 
by melatonin stimulating phosphorylation of CaM through 
protein kinase C α (PKCα) [50–52]. Further studies have 
also shown that human breast cancer xenografts exhibit 
a day-night rhythm of tumour proliferation, fatty acid 
uptake, metabolism, and signal transduction activity, all 
believed to be driven by the nocturnal, circadian rhythm 
melatonin signal [39, 46].
Clock genes
In mammals, two to ten percent of all gene expression 
is rhythmic, and these clock genes, located in peripheral 
oscillators and found in almost all nucleated cells of the 
human body, regulate practically every biological process 
and function in a time-specific manner to help maintain 
circadian rhythms [28, 53]. Aiding in the maintenance 
of the circadian clock, the core clock genes function 
through two interlocking regulatory feedback loops driven 
by the genes CLOCK/Npas2, Bmal1, Period (Per) and 
Cryptochrome (Cry) [54] (Figure 1). In one regulatory 
loop, two transcriptional activators, BMAL1 (brain and 
muscle ARNT-like protein 1) and CLOCK (circadian 
locomotor output cycles kaput), form CLOCK/BMAL1 
heterodimers in the nucleus where they activate the 
expression of the Per and Cry genes by binding to 
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E-box promoter sequences (Figure 1). In the cytoplasm, 
the PER and CRY proteins form complexes with each 
other, move into the nucleus, and inhibit the activity 
of the CLOCK/BMAL1 heterodimers, thus causing 
transcription of the Per and Cry genes to stop (Figure 1). 
In the other regulatory loop, the expression of the Bmal1 
gene is controlled through CLOCK/BMAL1 heterodimer 
formation in the nucleus (Figure 1). These heterodimers 
bind to the E-box promoter sequences of genes that encode 
the retinoic acid-related orphan nuclear receptors (ROR), 
Rev-erbα and Roraα; The Rev-erbα and Roraα proteins 
then compete for the ROR element (RORE) in the Bmal1 
promoter and suppress or activate Bmal1 expression, 
respectively (Figure 1).
Through utilization of these circadian feedback 
loops, the precision of the mammalian clock is controlled 
through post-translational modifications [55]. Casein 
kinase one epsilon (CKIε) and casein kinase one delta 
(CKIδ), are the two main kinases responsible for the 
phosphorylation of the PER and CRY proteins [28]. 
Through the activity of these kinases, by the end of a 
regular circadian cycle, the PER1 and PER2 proteins have 
almost entirely undergone degradation, thereby preventing 
CLOCK/BMAL1 suppression in the nucleus and initiating 
the start of the next circadian cycle [56]. Nuclear 
entry of the PER and CRY proteins also acts as a vital 
checkpoint for progression of the circadian cycle, with a 
co-dependency existing between the two proteins [28]. The 
presence of CRY1 and PER2 interaction in the cytoplasm 
results in PER2 stability by preventing its degradation 
through CKIε phosphorylation, and thus permits nuclear 
translocation and suppression of the CLOCK/BMAL1 
heterodimer (Figure 1). Alterations to the balance 
between the CRY and PER proteins can therefore lead 
to changes in the circadian cycle. For example, the Tau 
mutation in the CKIε gene leads to altered levels of 
phosphorylation of PER proteins, resulting in a shortened 
circadian length [57]. Furthermore, Per1 and Per2 respond 
and adapt faster than Cry1 to circadian disruption, and as a 
result, circadian disruption can induce internal phase shifts 
within the circadian clock [58].
Clock genes and breast cancer
In addition to helping regulate circadian oscillations, 
the core clock genes have been shown to influence cancer 
related mechanisms such as cell proliferation, apoptosis, 
cell cycle, and tumour-suppressor genes. Studies have 
shown that overexpression of Per1 and Per2 inhibits the 
growth of various cancer cells. Period1 plays a role in 
apoptosis in human cancer cells, with its down-regulation 
stopping apoptosis and its overexpression increasing DNA 
Figure 1: Overview of the two interlocking circadian clock regulatory feedback loops. The blue arrows represent the 
BMAL1/CLOCK regulatory feedback loop which controls the expression of the Per and Cry genes. The orange arrows represent the 
regulatory feedback loop that controls the expression of the Bmal1 gene and formation of the BMAL1/CLOCK heterodimer.
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damage-induced apoptosis [59]. The Per2 gene has been 
shown to act as a tumour suppressor in luminal breast 
cancers by linking the circadian oscillator system to the 
ERα function [60]. Human Per2 is estradiol (E2) inducible 
in mammary cells, causing Per2 expression to lower ERα 
activation through the consumption of E2 [27]. Since ER 
activation through E2 results in DNA adduct formation, 
mammary cell proliferation, and genotoxic waste, the 
reduction in ERα activation by Per2 expression results in 
an oncostatic effect [61].
The overexpression of CLOCK has been linked to 
increased proliferation in luminal breast cancer cells [62]. 
This oncogenic influence of CLOCK is likely associated 
with estrogen-estrogen receptor α (E2- ERα) signaling, 
with E2 promoting the binding of ERα to estrogen 
response elements (EREs) of the CLOCK promoter and 
increasing transcription [62]. Numerous single nucleotide 
polymorphisms (SNPs) in the CLOCK gene have also 
been correlated with increased breast cancer risk [63]. 
Interestingly, 67% of the SNPs were associated with non-
luminal breast cancers, indicating that CLOCK expression 
most likely plays a role in both luminal and non-luminal 
breast cancer [63]. The same study also showed that 
CLOCK knockdown results in increased expression of 
various tumour suppressor genes and decreased expression 
of multiple oncogenes, indicating an oncogenic influence 
by CLOCK on breast cancer development [63].
Unlike CLOCK, BMAL1 has been reported as having 
oncostatic effects in cancer development. Specifically, 
BMAL1 has been shown to suppress cancer cell invasion 
by antagonizing the oncogene B-cell lymphoma w 
(Bcl-w), thus suppressing matrix metalloproteinase-2 
(MMP-2) accumulation and blocking the PI3K-AKT-
MMP2 signaling pathway [64]. Furthermore, loss of 
Bmal1 expression has been shown to result in lower 
transcript levels of Per1 and Per2, and increased protein 
levels of cyclin D1 [65]. The cyclin D1 protein is involved 
in promoting transition from the G1 to the S-phase in 
the cell-cycle by binding to cyclin-dependent kinase 4 
(CDK4) or CDK6 proteins, and its overexpression 
enhances the activity of ERα and counteracts the breast 
cancer-suppressor gene breast cancer 1, early onset 
(BRCA1) [66]. In mice and cancer patients, overexpression 
of Cyclin D1 is associated with mammary tumourigenesis 
and poor medical prognosis, respectively [27, 67].
As an extension of the influences of CLOCK and 
Bmal1 on cancer development, the CLOCK/BMAL1 
heterodimer has been shown to regulate cell-cycle genes 
that are involved in breast cancer progression [27]. This 
regulation occurs in an oncogenic manner through the 
activation of WEE1 G2 checkpoint kinase (WEE1), 
and an oncostatic manner through the suppression of 
myc avian myelocytomatosis viral oncogene homolog 
(c-MYC) [27, 67–69]. In breast cancer cells, the G1 cycle 
checkpoint is often aberrantly regulated, allowing cells 
with DNA damage to enter the S phase [70]. When this 
occurs, cancer cells rely on the G2 check point for damage 
repair before entering mitosis [70]. Over expressed in 
breast cancer cells, the WEE1 protein is a nuclear kinase 
that helps regulate transition from the G2 phase to mitosis 
by inhibiting the activity of the CDK1 protein, thus 
increasing DNA repair in cancer cells prior to mitosis 
[70, 71]. c-Myc is a regulator gene whose overexpression 
causes increased cell proliferation through cyclin activity 
and lowered apoptosis through Bcl-2 activity, with c-Myc 
overexpression eventually leading to hyperplasia and 
tumour development [67].
Although both the Cry genes may be implicated in 
breast cancer development, the majority of findings thus 
far have pinpointed Cry2 as playing a more prominent 
role. In a study investigating the potential significance 
of Cry2 in breast cancer development, experimenters 
identified SNPs in the Cry2 gene as potential biomarkers 
for increased risk of breast cancer, with the variants 
having a stronger association with non-luminal breast 
cancers [72]. The results also illustrated that the degree 
of Cry2 expression can vary between breast cancer types, 
with the non-luminal breast cancers having higher levels 
of Cry2 expression when compared to luminal breast 
cancers [72]. Finally, CRY2 knockdown in MCF-7 cancer 
cells resulted in aberrant regulation of cell differentiation, 
proliferation, motility, angiogenesis, and apoptosis, thus 
suggesting a tumour-suppressor role for CRY2 in breast 
cancer development [72].
As discussed thus far, there is clear evidence 
connecting the circadian clock and its components to 
breast cancer development through hormone activity 
and the influence of core clock genes. However, there is 
another area of study that may provide the crucial link in 
CD-induced breast cancer.
EPIGENETICS
Epigenetics is the study of heritable changes in gene 
expression or cellular phenotype by mechanisms that do 
not involve direct changes to the DNA sequence. Two 
examples of epigenetic mechanisms are DNA methylation 
and RNA associated silencing.
DNA methylation
The biochemical process of DNA methylation 
involves the addition of a methyl group to the 5’ 
carbon of the cytosine nucleotide in DNA, with 
cytosine DNA methylation being one of the most 
widely studied and known epigenetic mechanisms 
[73]. This process plays a crucial role in normal cell 
development, cell proliferation, and maintenance of 
genome stability [73]. In mammals, DNA methylation 
is mediated by DNA methyltransferase enzymes. DNA 
methyltransferase 1 (DNMT1) is the major enzyme 
involved in maintenance DNA methylation and is 
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responsible for copying DNA methylation patterns 
to daughter strands during DNA replication [74]. DNA 
methyltransferase 3a (DNMT3a) and DNMT3b act as 
de novo methyltransferases that target unmethylated and 
hemimethylated sites, and are responsible for DNA 
methylation patterns early in development [75]. 
Finally, although DNMT3L has no methyltransferase 
activity, it interacts with DNMT3a and 3b to help 
establish maternal methylation imprints and appropriate 
expression of maternally imprinted genes [76].
The activity of DNA methyltransferases mostly 
occurs in the context of CG dinucleotides (CpG), with 
about 60–80% of CpG cytosines being methylated in 
mammals [77]. Hypermethylation of CpG dinucleotides, 
which is over methylation of DNA, is linked to genomic 
instability due to silencing of DNA repair genes, silencing 
of tumour-suppressor genes, and compaction of chromatin 
[78]. Hypomethylation of CpG dinucleotides, which is the 
absence of cytosine methylation, has been linked to gene 
reactivation, chromosomal instability, and up-regulation 
of proto-oncogenes [79]. The ability of DNA methylation 
to cause transcriptional repression is achieved through 
methyl CpG-binding domain (MBD) proteins, with these 
proteins selectively interacting with methylated DNA 
in order to achieve gene silencing [73]. Many genes in 
mammals also have CpG islands that are found close to 
promoter regions of genes [80]. These short stretches 
of DNA, located in the 5`-regions of 60% of all genes, 
contain high concentrations of CpGs, with the methylation 
status of these islands usually being reversed in tumour 
cells when compared to normal cells for genes that play a 
role in cancer development [78].
DNA methylation and breast cancer
In recent years, recognition of the role DNA 
methylation plays in the etiology of breast cancer has 
increased. In terms of hypermethylation, more than 100 
genes have been reported to be hypermethylated in breast 
tumours or breast cancer cell lines, with many of these 
genes playing a role in DNA repair, cell-cycle regulation, 
apoptosis, and metastasis. Among the hypermethylated 
genes involved in DNA repair are BRCA1 and RAD9 
Homolog A (RAD9) [78]. BRCA1 is an extensively studied 
tumour-suppressor gene involved in double-stranded 
DNA breaks through homologous recombination repair 
in late S and G2 phases of the cell-cycle, while RAD9 is 
involved in base excision repair, mismatch repair, and 
homologous recombination repair [81, 82]. Some of the 
hypermethylated genes involved in cell-cycle regulation 
are dickkopf WNT signaling pathway inhibitor 3 (DKK3) 
and wnt inhibitory factor 1 (WIF1), and some of the genes 
involved in apoptosis are homeobox A5 (HOXA5) and 
target of methylation-induced silencing (TMS1) [78, 83]. 
Both WIF1 and DKK3 are Wnt signaling-pathway 
antagonists, with increased Wnt pathway activity being 
associated with lowered cell senescence, resistance 
to apoptosis, and increased resistance to anti-cancer 
therapies [83, 84]. HOXA5 expression increases apoptotic 
activity in a p53-dependent manner and through caspase 
activity [85]. Although the exact mechanism by which 
TMS1 induces apoptosis has not yet been fully elucidated, 
TMS1 is a proapoptotic gene and a sensitive prognostic 
marker for tumourigenesis [86]. Hypermethylation of 
tumour-suppressor genes can also be an early marker in 
breast cancer and be compounded by DNMT activity. For 
example, hypermethylation of the tumour-suppressor gene 
Ras association domain-containing protein 1 (RASSF1A) 
is an early epigenetic event in breast cancer, and it has 
been shown to increase linearly in benign breast tissue of 
women between 23 and 55 years of age [87].
The hypermethylation status of certain genes has 
also been linked as a predictor of hormone receptor 
development in breast carcinogenesis. DNA methylation 
of estrogen receptor 1 (ESR1) and progesterone receptor 
(PR) promoters has been proposed as a mechanism for 
the development of ER-negative tumours [88–90]. 
A recent clinical study has also shown that ERα-promoter 
hypermethylation has a strong correlation with ER-
negative tumours, PR-negative tumours, and non-luminal 
tumours [91]. Furthermore, another study conducted a 
CpG methylation-pattern analysis on known breast cancer 
tumour-suppressor genes in order to correlate methylation 
status with hormone expression. The study found that a 
combination of reversion-induced LIM (RIL) and cadherin 
13 (CDH13) hypermethylation was strongly correlated 
with ER- and PR-negative tumours, while a combination 
of high in normal (HIN-1) and RASSFIA methylation was 
associated with ER- and PR-positive tumours [92].
Although DNA hypomethylation was the first 
epigenetic abnormality discovered in human tumours, it 
was somewhat cast into the shadows at the expense of 
tumour-suppressor genes and hypermethylation [93, 94]. 
More widely spread across the genome and associated 
with repetitive DNA elements, DNA hypomethylation 
was not only ignored, but it was more difficult to pinpoint 
with limited technology [93, 95]. However, as scientific 
technologies have continued to improve, the role of 
DNA hypomethylation in breast cancer development has 
become more illuminated.
Among the types of repetitive DNA elements that 
are affected by global hypomethylation are transposable 
DNA elements [96]. Constituting 11% and 17% of the 
human genome, long interspersed nucleotide element-1 
(LINE-1) and Alu are major components of these 
repetitive transposable elements [97]. Given their vast 
distribution in the genome, these regions are often used 
as markers for genome-wide methylation status [98]. 
In addition, hypomethylation of these regions has been 
linked to various cancers, with lower methylation causing 
transcriptional activation, retrotransposition, genomic 
instability, and the decrease in methylation correlating 
with cancer progression [98, 99]. In a recent study, 
experimenters investigated the link between Alu and 
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LINE-1 hypomethylation and breast cancer subtypes 
[98]. The results showed that Alu hypomethylation 
was correlated with an ER-negative status in invasive 
breast cancer (IBC), while LINE-1 hypomethylation 
was correlated with an ER-negative status and HER2 
expression [98]. The findings also suggested that LINE-1 
hypomethylation is an early event in breast cancer 
development, while Alu hypomethylation is a late event in 
breast cancer progression, and that lower Alu methylation 
is associated with poorer disease-free patient survival [98].
Among the advances in technology that have 
allowed for further insight into DNA hypomethylation 
and cancer research is whole-genome shotgun bisulfite 
sequencing (WGSBS). Through the use of this technique, 
researchers have identified that cystosines methylated 
in the CpG content are almost completely methylated 
in pluripotent cells, but are only partially methylated in 
somatic cells [100]. Regions of these partially methylated 
cystosines can be found in nearly 40% of the genome 
and have been classified as partially methylated domains 
(PMDs) [100]. Although hypomethylation has been 
traditionally associated with increased gene expression, 
a recent study utilized WGSBS on HER2-positive breast 
cancer cells and found that global hypomethylation is 
associated with PMDs and gene silencing [101]. 
Specifically, a significant fraction of genes within the 
hypomethylated regions showed allelic DNA methylation 
at one allele, and no methylation coupled with repressive 
chromatin marks H3K9me3 or H3K27me3 at the other 
allele [101]. The data from the experiment also suggest 
that global hypomethylation in breast cancer likely occurs 
through gradual loss of DNA methylation instead of an 
active mechanism involving demethylating enzymes, 
and that this gradual global hypomethylation most likely 
triggers the repressive chromatin domains [101].
Although hypomethylation of transcription regulatory 
regions in breast cancer is rare when compared to 
hypermethylation of CpG islands, it still does occur. For 
example, the gene encoding protease urokinase-type 
plasminogen activator (PLAU/uPA) is hypomethylated and 
over expressed in conjugation with tumour progression in 
breast cancers, with increased uPA expression resulting in 
increased tumour aggression and poor clinical outcome 
[102, 103]. A high-resolution analysis of DNA methylation 
in breast cancer also identified approximately 1500 regions 
that are hypomethylated [78, 104, 105]. Taken together, 
this evidence, in combination with the previous studies 
discussed, indicates that many of these hypomethylated 
regions may not only contribute to genomic instability, 
but probably contain genes, regulatory sequences, or 
mechanisms involved in breast cancer development.
DNA methylation and circadian rhythms
Although not many studies have demonstrated a 
direct role for DNA methylation in the circadian clock, 
there is evidence suggesting that this epigenetic process 
may play a pivotal role in influencing circadian rhythms. 
Furthermore, through numerous studies, every core clock 
gene has been identified as being aberrantly methylated 
in various human malignancies [106]. Among these 
malignancies is breast cancer, with many studies illustrating 
methylation profiles of the core clock genes that are 
consistent with the aberrant expression patterns previously 
discussed.
A recent study investigated the role of DNA 
methylation on circadian behaviour by using a mouse 
model system and measuring the effect of altered day 
length on global DNA methylation within the SCN [107]. 
The results showed that mice entrained to a 22-hour 
day had an altered endogenous free-running period 
(FRP) and 1,294 differentially methylated regions when 
compared to mice entrained to a regular 24-hour day 
[107]. Among the differentially methylated regions 
were hypermethylated Per2 and Cry1 promoters, and 
hypomethylated CLOCK promoters [107]. To verify 
further the influence of DNA methylation on FRP, the 
experimenters inhibited methylation through the global 
DNMT inhibitor zebularine, and the results showed 
a significant suppression of FRP changes in the DNMT-
inhibited mice. Finally, the study illustrated that the 
aberrant changes to FRP through DNA methylation are 
plastic, with short-day mice that are entrained back to a 
regular 24-hour day showing a reversion in FRP and DNA 
methylation levels [107]. These results represent the first 
evidence of a direct role for dynamic DNA methylation in 
the circadian clock, and illustrate that the activity of the 
enzymes catalyzing DNA methylation may be influenced 
by light-dependent induction or repression.
As discussed previously, the core clock genes can 
influence breast cancer development through a variety of 
mechanisms. It is therefore not surprising that promoter 
methylation profiles in breast cancer correlate with 
the oncogenic and oncostatic actions of the core clock 
genes. For example, a pair of studies showed that all 
the breast cancer types tested had CLOCK-promoter 
hypomethylation and Cry2-promoter hypermethylation 
when compared to controls [63, 72]. Another study 
illustrated that 95% of the breast cancer cells tested 
in women showed aberrant promoter methylation in 
the Period genes, including Per1- and Per2-promoter 
hypermethylation [108]. The methylation status of the 
Per genes was also linked to increased expression of 
ERBB2, the gene used to help classify breast cancers by 
type and a prognostic marker that negatively correlates 
with disease-free survival and overall survival [108, 109].
Even though there is some evidence for the 
influence of DNA methylation on circadian rhythms and a 
consistent promoter-methylation pattern between the core 
clock genes and breast cancer development, skepticism 
remains about the actual role of DNA methylation in 
circadian rhythms. The question remains whether aberrant 
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DNA methylation at clock genes in cancer cells is the 
cause of circadian disruption, or simply a bystander effect 
of deregulated circadian rhythms. One theory, based 
on data from Neurospora, suggests that the aberrant 
methylation does not play a causative role and is instead 
a readout [106]. In either case, the epigenetic influence 
on CD-induced breast cancer likely extends into another 
epigenetic mechanism.
MicroRNAs
Epigenetic control can also be mediated by means of 
small regulatory RNAs, specifically microRNAs (miRNAs). 
Mature miRNAs are abundant, small, single-stranded, 
noncoding RNAs that are potent regulators of gene 
expression [110]. Functional (mature) miRNAs can 
originate from either the exons or introns of non-coding 
genes, or introns of protein-coding genes [111–113]. The 
miRNAs found within the transcripts of other genes are 
under direct transcriptional control of those genes, while 
miRNAs found within intergenic regions are under their 
own control [111, 112]. Furthermore, miRNAs can be 
transcribed as a single unit or part of a polycistron, with 
polycistron miRNA expression acting as an efficient 
mechanism to target a single mRNA or to target multiple 
mRNAs in a signal molecular pathway [114–116].
The production and development of mature miRNAs 
in mammals involves multiple steps and numerous 
proteins and complexes [117]. First, transcription results 
in primary miRNA (pri-miRNA) in the nucleus, with 
the leading candidate for this pri-miRNA transcription 
being RNA polymerase (pol) II, but evidence showing 
that RNA pol III may also play a role in some transcripts 
[118, 119]. The RNase III endonuclease Drosha then 
forms a microprocessor complex with the protein DGCR8/
Pasha, and digests the pri-miRNA to release a 60–70 
nucleotide (nt) stem-loop intermediate known as precursor 
miRNA (pre-miRNA), with the base of the stem loop 
having a 5′ phosphate and a two nucleotide 3′ overhang 
that is characteristic of RNase III cleavage [120, 121]. 
The pre-miRNA is then transported to the cytoplasm by 
Ran-GTP and the export receptor Exportin5, where it 
undergoes more processing by the enzyme Dicer [121]. 
With the nuclear processing by Drosha defining one end 
of the pre-miRNA, the other end is processed by Dicer, 
and as this enzyme is also an RNase III endonuclease, the 
cleavage results in a 5′ phosphate and a two nucleotide 
3′ overhang in place of the stem loop, as well as the 
formation of a mature double stranded miRNA duplex 
(miRNA:miRNA*) [121, 122].
In order to control the translation of their target 
mRNAs, the mature miRNA duplex associates with 
the RNA-induced silencing complex (RISC), which is 
composed of the proteins Argonaute (AGO), protein 
activator of the interferon-induced protein kinase (PACT), 
fragile X mental retardation protein (FXR), tudor 
staphylococcal nuclease (Tudor-SN), as well as other 
proteins [123]. However, evidence shows that the 
miRNA:miRNA* duplex is generally short-lived in 
comparison to the mature single-stranded miRNA, with 
fragments from the opposing arm (miRNA*) being 
found in much smaller quantities in libraries of cloned 
miRNAs [124, 125]. Although it appears that the AGO 
protein initiates the dissociation of one of the strands, 
the exact mechanism of strand selection in mammals has 
yet to be elucidated [116]. However, one theory suggests 
that the miRNA* is peeled away and degraded when the 
miRNA:miRNA* duplex is loaded into RISC because the 
other arm of the duplex has a less-tightly paired 5′ end, 
and as a result, it is more thermodynamically favourable to 
separate the duplex in this manner when association with 
RISC occurs [126].
Once the miRNA-RISC complex is assembled, it 
then binds to the 3′ UTR (untranslated region) of target 
mRNAs, resulting in posttranscriptional down regulation 
of gene expression by one of two mechanisms; mRNA 
cleavage or translational repression. If there is extensive 
complementarity between the miRNA and the 3′ UTR, 
then cleavage of the mRNA occurs [123]. However, if 
the homology between the miRNA and 3′ UTR is not 
sufficient, productive translation can be repressed through 
processing bodies (P-bodies) [127]. In mammals, binding 
is usually not very high in complementarity, so not only 
is suppression of gene expression by miRNAs usually 
achieved through inhibitory machinery, but each miRNA 
has numerous targets and can influence the expression of 
many different genes [128].
MicroRNAs and breast cancer
The activity of mature miRNAs has an impact on 
a variety of cancer related processes, such as cellular 
differentiation, proliferation, apoptosis, and genome stability. 
One role by which miRNAs can influence these processes 
is by acting as oncogenic miRNAs (oncomiRs). Among 
the most well-studied and abundant oncomiRs in various 
cancers, including breast cancer, is miR-21 [116]. With its 
expression being linked to induction by signal transducer 
and activator of transcription 3 (STAT-3), a protein shown 
to be overexpressed in breast cancer and linked to various 
oncogenes, miR-21 is often overexpressed as well, 
resulting in the negative regulation of various tumour-
suppressor genes [116, 129]. Specifically, miR-21 has 
been shown to down regulate the expression of the tumour 
suppressors phosphatase and tensin homolog (PTEN) and 
programmed cell death 4 (PDCD4) [130, 131]. In breast 
cancer, PTEN coordinates G1 cell-cycle arrest by down 
regulating the cyclin D1 protein and increasing p27 
expression, causing reduced cell growth and increased 
apoptosis [132, 133]. PDCD4 inhibits CDK1 activity 
through induction of p21, and loss of PDCD4 is linked 
to breast cancer development [130, 134]. An experiment 
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also showed that knockdown of miR-21 in MCF-7 and 
MDA-MB-231 breast cancer cell lines inhibited in vitro 
growth and migration, as well as in vivo growth [135].
The expression and activity of oncomiRs can also 
extend into miRNA clusters. For example, the miR-17–92 
cluster was among the first miRNA groups discovered 
to be deregulated in various cancers, including breast 
cancer [116]. Containing six miRNAs that are transcribed 
together as a single polycistron, up-regulation of these 
miRNAs has been linked with increased levels of cell 
proliferation and lowered apoptosis [116]. Another oncomiR 
cluster, the miR-221/222 tandem, has been linked to 
ER-negative and basal-like breast cancers [136, 137]. In 
terms of ER-negative breast cancer, miR-221/222 was 
shown to target the 3′ UTR of ERα, resulting in lowered 
ERα protein levels in MCF-7 breast cancer cell lines 
and increased resistance to TAM treatment [137]. Basal-
like breast cancer is notoriously more aggressive than 
all the other breast cancer types, and it seems that this 
aggressiveness may be linked to miR-221/222 expression 
[136]. Epithelial-to-mesenchymal transition (EMT) is 
the process by which epithelial cells lose the adherent 
properties and tight junctions that keep them in 
contact with neighbouring cells and gain mesenchymal 
properties, causing gene expression changes within the 
cells, resistance to apoptosis, and the ability to break 
through the basal membrane and migrate over long 
distances [138]. Evidence shows that the miR-221/222 
cluster promotes EMT by repressing expression of the 
trichorhinophalangeal syndrome 1 (TRPS1) protein, which 
in turn results in an increase of the EMT-promoting protein 
zinc finger E-box binding homeobox 2 (ZEB2), thus 
potentially contributing to the more aggressive clinical 
behaviour of basal-like breast cancer [136].
In addition to acting as oncomiRs, miRNAs 
can also act as tumour suppressors. Several individual 
miRNAs have been identified as tumour suppressors in 
breast cancers. Among these are miR-99a and miR-140. 
MicroRNA 99a overexpression has been shown to induce 
G1 cell-cycle arrest and apoptosis by lowering expression 
of the mammalian target of rapamycin (mTOR) gene, 
with miR-99a being a potential candidate for use as a 
therapeutic strategy for effectively controlling breast 
cancer development [139]. The transcription factor sex 
determining region Y-box 2 (SOX2) has been reported 
to be overexpressed in breast cancers and identified 
as playing a role in the early steps of tumour initiation 
through cancer stem cells (CSCs) [140]. SOX2 has 
been identified as a target of miR-140, and in ER-α 
breast cancer cells, estrogen stimulation lowers miR-140 
expression through ER-α binding to an ERE flanking the 
mir-140 promoter, thus increasing levels of SOX2 [141]. 
MicroRNA tumour-suppressor activity can also extend 
into miRNA clusters and result in more potent regulation 
than through individual miRNAs. For example, the 
miR-143/145 cluster has been shown to lower ERBB3 
protein levels and cause less proliferation and invasion 
in breast cancer cells [142]. Interestingly, although the 
miRNAs are still capable of causing tumour suppression 
effects on their own, expression of the miR-143/145 
cluster results in more potent tumour suppression through 
a synergistic effect [142].
MicroRNAs and circadian rhythms
MicroRNA activity has been shown to be associated 
with circadian rhythms through rhythmically regulated 
miRNAs and through direct influence on the circadian 
cycle. Numerous studies have illustrated that miRNAs 
oscillate throughout a 24-hour circadian day. For 
example, in Arabidopsis, miRNAs-167, 168, 171, and 
398 were shown to oscillate, based on environmental 
light; daytime levels were also reported as higher than 
nighttime levels, and the oscillation of these miRNAs was 
governed through photic control and not an internal clock 
[143]. A microarray-based study on mouse livers also 
revealed that over 13% of the probed miRNAs exhibited 
circadian expression patterns [144]. Among these miRNAs 
were miR-181d and 191, with an inversely-correlated 
expression pattern being observed between these miRNAs 
and their respective targets, CLOCK and Bmal1 [144]. 
In another study conducted on HeLa cell lines, results 
showed that the miR-192/194 cluster directly regulates the 
entire Period gene family, with increased expression of 
the miR192/194 tandem causing lowered expression of the 
Period genes and a shortening of the circadian cycle [145].
Of the miRNAs involved in circadian rhythms, 
miR-132 may potentially play a very prominent role, 
especially when considering the link between circadian 
rhythms and breast cancer. A rodent model experiment 
showed that miR-132 exhibited oscillatory expression in 
wild-type mice, but not in circadian mutant mice [146]. 
Further investigation has also illustrated that miR-132 is 
induced by light within the SCN and that it has the capacity 
to entrain or reset the circadian clock [147]. The proposed 
model suggests that nocturnal light triggers the chromatin 
remodeling gene methyl CpG binding protein 2 (MeCP2), 
which triggers the transcription of various light-responsive 
genes, including the miR-132 promoter, Per1, Per2, PABP 
interacting protein 2A (Paip2A), and B-cell translocation 
family member 2 (Btg2) [147]. As PERIOD, PAIP2A, 
and BTG2 protein levels increase, PAIP2A and BTG2 
levels eventually reach a certain level and Per1 and Per2 
transcription is inhibited by these two proteins [147]. 
Simultaneously, levels of mature miR-132 also increase 
through miR-132 promoter transcription and processing 
of pri-miRNA into functional miR-132 [147]. As levels of 
mature miR-132 increase, translational repression of its 
targets Mecp2, Paipa2A, and BTG2 eventually occurs, thus 
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restoring homeostasis and resetting the induction caused to 
the circadian clock by nocturnal light [147].
Interestingly, a recent study has reported that miR-132 
levels are lowered in breast cancer cells, with miR-132 being 
identified as a tumour suppressor by inhibiting proliferation, 
migration, invasion, and metastasis [148]. Therefore, by 
extension, the combination of light at night and increased 
breast cancer risk through shift work could potentially 
result in an aberrant compounded effect through lower 
miR-132 expression. Due to increased risk of breast cancer 
development, miR-132 levels may be lowered, and as 
a result, further nocturnal exposure to light would not 
only increase deregulation of the circadian clock due to 
the inhibition of homeostasis induced by miR-132, but 
also cause lowered oncostatic activity through increased 
transcriptional inhibition of the Period genes by PAIP2A 
and BTG2.
Although none of the research discussed thus far 
has investigated the link between epigenetics, circadian 
disruption, and breast cancer directly, the fact that the 
studies discussed have dealt with parts of this equation and 
illustrate potential overlap, demonstrates that a potentially 
substantial link may exist between all three factors.
CD-INDUCED BREAST CANCER: AN 
EPIGENETIC LINK?
As discussed thus far, numerous studies have 
investigated the link between circadian rhythms and breast 
cancer, epigenetics and breast cancer, and epigenetics and 
circadian rhythms. However, to date, only a handful of 
studies have incorporated all three factors and investigated 
the link between CD-induced breast cancer and epigenetic 
modifications. One of these studies incorporated a 
rodent model to investigate global methylation, while the 
other studies were conducted on human blood samples 
and focused on the influence of shift work on DNA 
methylation in peripheral blood cells.
The rodent model study, conducted to investigate 
the link between CD-induced breast cancer and epigenetic 
modifications, involved measuring the effect of circadian 
disruption on global methylation levels and the effect of 
melatonin on this relationship [149]. Three groups were 
used in the study: a control group, a light at night (LAN) 
group, and a LAN plus MLT group, with all three of the 
groups being injected with the 4T1-murine breast cancer 
cell line. The results showed that the LAN group had 
~30% less global methylation and larger tumour size when 
compared to the control group, while the LAN+MLT group 
only showed a ~10% decrease in global methylation and the 
smallest amount of tumour growth out of all three groups 
[149]. These results not only reiterated the important role 
that MLT plays in breast cancer development, but illustrated 
the important role that DNA methylation may play in 
CD-induced breast cancer and that melatonin levels may be 
linked to the aberrant DNA methylation that is occurring.
In a genome methylation analysis of 5,409 CpG 
sites on nurse blood samples, data showed that 3359 
(66.4%) of the sites were hypermethylated and 1,816 
(33.6%) were hypomethylated in long-term shift workers, 
as compared to daytime workers [150]. Many of these 
differentially methylated CpG sites were located near 
the promoter sequences of circadian-related and cancer-
relevant genes. Specifically, aberrant methylation of the 
circadian genes CLOCK and Cry2 was reported, with 
shift workers exhibiting CLOCK hypomethylation and 
Cry2 hypermethylation when compared to day workers, 
a pattern that has been associated with breast cancer and 
discussed previously [63, 72]. In another study, a total of 
50 CpG sites across 26 unique imprinted genes showed 
significant differences in methylation between shift 
workers and day workers, with a tendency towards more 
hypomethylation than hypermethylation [151]. The genes 
that showed the highest variation in methylation, distal-
less homeobox 5 (DLX5) and tumour protein 73 (TP73), 
are genes that are both linked to cancer development [151]. 
The DLX5 gene is a transcriptional factor that promotes 
cell proliferation through up-regulation of c-MYC 
promoter activity and its expression has been linked 
with breast cancer, while the TP73 gene is an important 
component of the p53 family of cell-cycle regulatory 
proteins and is altered in the majority of cancers [152, 
153]. Together, these two studies were among the first to 
illustrate that shift work can result in aberrant changes to 
DNA methylation at specific genes that are not only linked 
to circadian rhythms, but also breast cancer development.
The most recent human blood-analysis study 
conducted a genome-wide CpG island methylation assay 
of blood samples at miRNA promoters [154]. The results 
illustrated that 50 CpG loci, corresponding to 31 miRNAs, 
were differentially methylated in shift workers when 
compared to day workers. Among the differentially 
methylated genes was hypermethylation of the promoter 
for miR-219, a miRNA that has been linked to breast 
cancer development and has been identified as a potential 
regulator of circadian duration via the modulation of 
CLOCK- and BMAL1-dependent Per transcription [146, 
154, 155]. To investigate further, the experimenters 
performed a genome-wide microarray on an overexpressed 
miR-219, MCF-7 breast cancer cell line, which identified 
319 differentially expressed transcripts [154]. Among 
the cancer-relevant pathways affected by these changes 
were increased apoptosis and immunomediated anti-
tumour activity. In a follow-up study, the experimenters 
investigated the role of another miRNA that showed 
significant promoter hypermethylation in the shift worker 
blood samples, miR-34b [156]. MCF-7 breast cancer cells 
were transfected with miR-34b, and 230 differentially 
expressed transcripts were identified, corresponding again 
to increased apoptosis and immunomediated anti-
tumour activity. Even though these studies analyzed DNA 
methylation levels at specific locations like the previous 
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experiments discussed, they were the first to illustrate 
that the epigenetic modifications involved in CD-induced 
breast cancer may extend into miRNA regulation.
FUTURE DIRECTIONS AND 
CONCLUSIONS
Although these handful of studies have provided 
valuable insights into the role of epigenetics in 
CD-induced breast cancer, there are glaring omissions 
and new directions that need to be investigated. First, 
none of the studies investigated the effect of CD on 
breast cancer development in mammary tissues. Second, 
although the experiment performed by Schwimmer et 
al. [149] did incorporate a circadian disruption scheme 
on a rodent model, the CD scheme was not very in-
depth because it did not incorporate varying degrees of 
CD, and the effect of CD was skewed due to artificial 
MLT levels. Third, all the studies focused on DNA 
methylation profiles, and although the Shi et al. [154] 
study identified aberrant DNA methylation at miRNA 
promoters, it did not measure direct changes in small 
RNA expression due to CD. Fourth, none of the studies 
considered the potential fluctuations in epigenetic 
modifications due to varying time points within a 
circadian cycle. Finally, although the studies illustrated 
epigenetic changes due to CD and their potential role 
in breast cancer development, none of the studies 
showed direct downstream consequences due to these 
epigenetic modifications. Therefore, to shed new light 
on the epigenetic modifications involved in CD-induced 
breast cancer, focus needs to be placed on investigating 
direct CD-induced changes in DNA methylation and 
miRNA levels in mammary tissues. To accomplish this, 
environmentally controlled experiments utilizing model 
systems and incorporating varying degrees of circadian 
disruption, mammary tissue extractions at various time 
points following CD, and mammary tissue extractions 
at specific time points within the circadian cycle, need 
to be performed. Although incorporating a murine breast 
cancer model has its drawbacks, such as the difficulties 
associated with interpreting the data because of the 
variation amongst the different models, or the fact that 
no single mouse model shows all the expression patterns 
and characteristics of human breast cancer, incorporating 
in-depth CD schemes on rodent model systems is the 
next logical extension [157]. This approach will allow 
for a closer investigation into the dynamic and influence 
of CD on breast cancer development, and new insights 
and directions may be generated that will lead to a 
deeper understanding of the potential carcinogenicity of 
varying degrees of CD, influence of epigenetic circadian 
fluctuations on tumourigenesis, and the direct effect of 
CD on epigenetic processes in mammary tissues.
In summary, several conclusions can be drawn from 
the existing literature:
• Circadian rhythms play a role in breast cancer 
development. Aberrant exposure to light during the 
dark phase of the circadian cycle can disrupt the 
activity of the SCN and cause aberrant changes to 
downstream processes that influence breast cancer. 
Among these processes are nocturnal MLT and core 
clock gene activity, with lower nocturnal MLT levels 
causing oncogenic effects and the core clock genes 
influencing a variety of cellular processes related to 
breast cancer.
• The role of epigenetics has been recognized increasingly 
in the etiology of breast cancer. Two epigenetic 
mechanisms, DNA methylation and miRNA activity, 
influence a variety of cellular processes related to breast 
cancer development. In addition, these two epigenetic 
processes have also been linked to circadian rhythms. 
DNA methylation has been shown to regulate core clock 
gene expression and may also potentially play a direct 
role in the circadian clock. While miRNAs have been 
shown to oscillate with the circadian cycle and directly 
influence components of the circadian clock.
• Although literature has provided evidence for a 
link between epigenetic modifications and circadian 
rhythms, with a clear overlap existing between these 
two processes and breast cancer development, only a 
handful of studies have incorporated all three factors 
and directly studied the epigenetic modifications 
involved in CD-induced breast cancer. Although these 
studies represent a good start, there are still many 
aspects and different directions that need to be addressed 
when investigating the epigenetic modifications 
involved in CD-induced breast cancer.
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